相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer
Liye Zhou et al.
CLINICAL CANCER RESEARCH (2020)
Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients
Biao Huang et al.
CANCER CELL INTERNATIONAL (2020)
EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma
Jessamy Tiffen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy
Juyan Zheng et al.
MOLECULAR CANCER (2020)
Trained Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition
Bram Priem et al.
CELL (2020)
EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived Suppressor Cells
Shuo Huang et al.
CANCER RESEARCH (2019)
STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion
Chuan-xia Zhang et al.
CELL DEATH AND DIFFERENTIATION (2019)
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
Daisuke Ennishi et al.
CANCER DISCOVERY (2019)
Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
Abdullah Al Emran et al.
TRENDS IN IMMUNOLOGY (2019)
STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models
Weiqing Jing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8+ T cell-mediated anti-tumor immunity
Rebekah Watkins-Schulz et al.
BIOMATERIALS (2019)
Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression
Shenying Fang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells
Julia Volckmar et al.
VACCINE (2019)
STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity
Rana Falahat et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
Xun Huang et al.
CELL (2018)
A phase II study of JS001, a humanized PD-1 mAb, in patients with advanced melanoma in China
Zhihong Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance
Megha Budhwani et al.
FRONTIERS IN ONCOLOGY (2018)
LBA15Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas
K J Harrington et al.
ANNALS OF ONCOLOGY (2018)
Design of amidobenzimidazole STING receptor agonists with systemic activity
Joshi M. Ramanjulu et al.
NATURE (2018)
Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways
Kai Li et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
Daniel Zingg et al.
CELL REPORTS (2017)
Resistance to PD1/PDL1 checkpoint inhibition
Jake S. O'Donnell et al.
CANCER TREATMENT REVIEWS (2017)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses (vol 162, pg 974, 2015)
Katherine B. Chiappinelli et al.
CELL (2017)
Perioperative treatment with the new synthetic TLR-4 agonist GLA-SE reduces cancer metastasis without adverse effects
Pini Matzner et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis
Tianli Xia et al.
CANCER RESEARCH (2016)
Targeting EZH2 in cancer
Kimberly H. Kim et al.
NATURE MEDICINE (2016)
NLRC5/MHC class I transactivator is a target for immune evasion in cancer
Sayuri Yoshihama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma
Jessamy Tiffen et al.
NEOPLASIA (2016)
STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice
Zili Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state
Annelien Verfaillie et al.
NATURE COMMUNICATIONS (2015)
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Seng-Ryong Woo et al.
IMMUNITY (2014)
Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Tobias Bald et al.
CANCER DISCOVERY (2014)
Immunotherapy for advanced melanoma: Fulfilling the promise
Helen Gogas et al.
CANCER TREATMENT REVIEWS (2013)
STING and the innate immune response to nucleic acids in the cytosol
Dara L. Burdette et al.
NATURE IMMUNOLOGY (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Structure of Human cGAS Reveals a Conserved Family of Second-Messenger Enzymes in Innate Immunity
Philip J. Kranzusch et al.
CELL REPORTS (2013)
The Polycomb complex PRC2 and its mark in life
Raphael Margueron et al.
NATURE (2011)
STING is a direct innate immune sensor of cyclic di-GMP
Dara L. Burdette et al.
NATURE (2011)
The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer
Liudmila L. Kodach et al.
CARCINOGENESIS (2010)
Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis
Simone Mocellin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
Helena Harlin et al.
CANCER RESEARCH (2009)
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Hiroki Ishikawa et al.
NATURE (2008)
Expression of polycomb group protein EZH2 in nevi and melanoma
Jonathan B. McHugh et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2007)
The retinoblastoma binding protein RBP2 is an H3K4 demethylase
Robert J. Klose et al.
CELL (2007)
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast
IM Bachmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The human genome browser at UCSC
WJ Kent et al.
GENOME RESEARCH (2002)
分享论文
